Antiviral therapy and serum AST would apparently affect the performance and cut-off values of serum AFP for detecting early-stage HCC and would be the two important and referable indicators when judging and selecting the specific cut-off values for HCC surveillance in different at-risk populations with different statuses of HBV suppression and liver inflammation. This evidence concerns the gene AFP and hepatocellular carcinoma.